At Seoul’s COEX Convention & Exhibition Center, a dialogue about the future of pharmaceuticals is set to unfold. From August 25 to 27, 2026, the global pharmaceutical industry will turn its attention to the grand opening of CPHI Korea 2026—the World Pharmaceutical Raw Materials Korea Exhibition. This event is not only a key gathering of Asia’s pharmaceutical industry chain, but also a pivotal opportunity for China and South Korea to deepen cooperation and pursue common development in the pharmaceutical sector.

South Korea, as the world’s 13th-largest pharmaceutical market, is undergoing a profound transformation from "generic drugs" to "innovation." Its enterprises have demonstrated strong competitiveness in cutting-edge fields such as synthetic biology and antibody-drug conjugates (ADCs). Meanwhile, China, as the world’s largest API producer and a major pharmaceutical market, boasts a complete industrial chain and rapidly growing innovation capabilities. The complementarity between the two countries’ pharmaceutical industries creates vast room for collaboration.

CPHI Korea serves as the critical bridge connecting this partnership. The exhibition will bring together over 270 exhibitors and more than 10,000 professional visitors from across the globe, covering the entire industry chain: APIs, intermediates, natural extracts, excipients, and biotech solutions. For Chinese enterprises, it is both a window to showcase products and expand channels, and a platform to understand South Korean market access rules and connect with international R&D resources.

During the exhibition, a series of high-level conferences and forums will delve into global pharmaceutical policies, technological innovation, and market trends. Chinese and South Korean enterprises will have the opportunity to engage in practical exchanges on topics such as technology transfer and commercialization, jointly exploring new cooperation models in R&D, manufacturing, and marketing.

From raw material supply to technical collaboration, market expansion to standard alignment, CPHI Korea offers full-spectrum connectivity for enterprises of both nations. Under the framework of RCEP, the coordinated development of China-Korea pharmaceutical industries will not only enhance the resilience and competitiveness of regional industrial chains, but also contribute Eastern wisdom to global healthcare advancement.

This August, at COEX Seoul, let us use raw materials as the medium and innovation as the engine to open a new chapter in China-Korea pharmaceutical collaboration.